Vertex licenses VX 787 for Influenza to Janssen Pharma.
Vertex Pharmaceuticals has announced that it has entered into a licensing agreement with Janssen Pharmaceuticals for the worldwide development and commercialization of VX 787, a novel medicine discovered by Vertex for the treatment of Influenza. As part of the agreement, Vertex will receive an up-front payment of $30 million from Janssen and has the potential to receive additional development and commercial milestone payments as well as royalties on future product sales. Vertex completed a Phase IIa study of VX-787 in 2013 that showed statistically significant improvements in viral and clinical measurements of influenza infection. VX-787 is designed to directly inhibit replication of the influenza virus.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins